Ⓐ
PeptiBrief
Evidence Library
analytical_and_preclinical_doping_study · 2021

Detection of LongR3-IGF-I, Des(1-3)-IGF-I and R3-IGF-I in blood and urine

Mongongu C, et al. · Drug Testing and Analysis
preclinicalPMID · 33587816Verified
View source
Plain-English summary

The paper confirms that Long R3 IGF-1 is an unapproved analogue relevant to doping control, not that it is safe or effective in humans.

Population
Laboratory samples and rats
Intervention
Administration or analytical testing of IGF-1 analogues including Long R3 IGF-1
Outcomes measured
Analytical detection|Blood and urine detectability|Doping-control relevance
Key findings
Long R3 IGF-1 and related analogues could be detected using validated analytical approaches and are relevant prohibited substances in sport.
Limitations
Analytical and animal study, not a human treatment trial. It provides no evidence of clinical benefit.
Risk of bias
Low for analytical detection questions but unsuitable for clinical efficacy conclusions.
Citation
Mongongu C, et al. (2021). Detection of LongR3-IGF-I, Des(1-3)-IGF-I and R3-IGF-I in blood and urine. Drug Testing and Analysis
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.